CB AC 02

Drug Profile

CB AC 02

Alternative Names: Placenta-derived mesenchymal stem cell therapies

Latest Information Update: 04 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CHA Bio & Diostech
  • Class Antidementias; Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 26 Sep 2016 Preclinical trials in Alzheimer's disease in South Korea before September 2016 (IV)
  • 26 Sep 2016 CHABiotech plans a phase I/II trial for Alzheimer's disease in South Korea (NCT02899091)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top